DTaP5-HBV-IPV-Hib pediatric hexavalent combination vaccine for use in children from 6 weeks through to 4 years of age

Obando-Pacheco, Pablo; Rivero‐Calle, Irene; Raguindin, Peter Francis; Martinón-Torres, Federico

doi:10.1080/14760584.2019.1690457

Cited by 9 publications

(3 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High combination vaccines are not only popular among parents who want to avoid suffering in their child. Compared to the classical vaccination, the multi-component version have proved to be safer, while ensuring proper immunity for the child, which could be the reason for more countries deciding to fund them from State budgets [21].…”

Section: Discussionmentioning

confidence: 99%

The popularity of the 5- and 6-component combination vaccines among infants' parents in a selected Primary Health Care Clinic

Wojczyk¹,

Podstawa²

2021

Med Srod.

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

The popularity of the 5- and 6-component combination vaccines among infants' parents in a selected Primary Health Care Clinic

Wojczyk¹,

Podstawa²

2021

Med Srod.

View full text Add to dashboard Cite

show abstract

“…Additionally, three of the four more promising vaccines are currently undergoing or have recently completed phase III clinical trials [ 120 ]. The pediatric hexavalent vaccine Shan 6 (NCT04429295) successfully demonstrated potent immunogenicity and a good safety profile in 2021 and is in the process of applying for New Drug Application approval [ 124 ]. Another promising candidate with its phase I clinical development conducted in 2019 is the LBVD vaccine, a combined diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and Hib vaccine [ 125 ].…”

Section: From Research To Real-world Experience: Currently Approved A...mentioning

confidence: 99%

The Promising Potential of Reverse Vaccinology-Based Next-Generation Vaccine Development over Conventional Vaccines against Antibiotic-Resistant Bacteria

Khalid

Poh

2023

Vaccines

View full text Add to dashboard Cite

The clinical use of antibiotics has led to the emergence of multidrug-resistant (MDR) bacteria, leading to the current antibiotic resistance crisis. To address this issue, next-generation vaccines are being developed to prevent antimicrobial resistance caused by MDR bacteria. Traditional vaccine platforms, such as inactivated vaccines (IVs) and live attenuated vaccines (LAVs), were effective in preventing bacterial infections. However, they have shown reduced efficacy against emerging antibiotic-resistant bacteria, including MDR M. tuberculosis. Additionally, the large-scale production of LAVs and IVs requires the growth of live pathogenic microorganisms. A more promising approach for the accelerated development of vaccines against antibiotic-resistant bacteria involves the use of in silico immunoinformatics techniques and reverse vaccinology. The bioinformatics approach can identify highly conserved antigenic targets capable of providing broader protection against emerging drug-resistant bacteria. Multi-epitope vaccines, such as recombinant protein-, DNA-, or mRNA-based vaccines, which incorporate several antigenic targets, offer the potential for accelerated development timelines. This review evaluates the potential of next-generation vaccine development based on the reverse vaccinology approach and highlights the development of safe and immunogenic vaccines through relevant examples from successful preclinical and clinical studies.

show abstract

“…3 The HV vaccination is completed usually within 1 year of age together with other pediatric vaccinations including rotavirus, pneumococcus conjugate vaccine and Men B. 4 …”

Section: Introductionmentioning

confidence: 99%

Real life hexavalent vaccination among children as a practical guide for public health professionals: Four years (from 2016 to 2019) of clinical practice in Sicily, Italy

Costantino

Cimino

Bonaccorso

et al. 2022

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Hexavalent (HV) vaccination is a priority for newborn protection and in Italy is included in the National Immunization Plan with a three doses cycle at 61, 121 and 301 days of age. A retrospective clinical study has been conducted to evaluate real life clinical practice of HV vaccination in the fourth most populous Italian Region. Data on the completion of the HV cycle, on the interchangeability between the two HV adopted in 2016–2017 (DTaP3-IPV-HB/Hib) and 2018–2019 (DTaP5-IPV-HB-Hib) and on the use above the established age, were collected in five Sicilian Local Health Authorities. Data showed an average 91.5% completion of the vaccination cycle at 24 months of age. The average age of administration was significantly higher in children who switched between the two hexavalent vaccines compared to those who completed the vaccination cycle with the same product ( p -value <.01). Interchangeability with one or two doses of HV was also documented in 17.8% (2018) and 16% (2019) of vaccinated infants. Co-administration with other vaccines included in the Sicilian Vaccination Schedule was 85% with anti-pneumococcal vaccination and 65% with anti-rotavirus vaccination. Children vaccinated above recommended age (from 15 to >36 months) significantly after the introduction of mandatory vaccination in Italy ( p -value <.001). This retrospective analysis will contribute to manage potential disruptions due to missed routine immunization opportunities, as the pandemic has caused, with strategies such as catch up above recommended age as well as interchangeability. Data could also help to demonstrate the need to optimize vaccine sessions through co-administration, that strongly contribute to increase vaccination coverage rates and respect of timing of vaccination schedules.

show abstract

DTaP5-HBV-IPV-Hib pediatric hexavalent combination vaccine for use in children from 6 weeks through to 4 years of age

Cited by 9 publications

References 62 publications

The popularity of the 5- and 6-component combination vaccines among infants' parents in a selected Primary Health Care Clinic

The popularity of the 5- and 6-component combination vaccines among infants' parents in a selected Primary Health Care Clinic

The Promising Potential of Reverse Vaccinology-Based Next-Generation Vaccine Development over Conventional Vaccines against Antibiotic-Resistant Bacteria

Real life hexavalent vaccination among children as a practical guide for public health professionals: Four years (from 2016 to 2019) of clinical practice in Sicily, Italy

Contact Info

Product

Resources

About